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fx) to the non-involved prostate. Planning constraints used 
were based on institutional procedures as well as from the 
FLAME trial, with small modifications in the boost plans. The 
dose distributions (with/without boost) were used to 
calculate the TCP and NTCP values for each patient. The TCP 
model used apparent diffusion coefficient maps to estimate 
cell densities while the NTCP models used were the 
conventional Lyman model for the rectum (late rectal 
bleeding grade >= 2; Rad. Onc, 73, 21-32, 2004) and the 
Poisson LQ model for the bladder (contracture; Ågren PhD 
thesis, 1995). 
 
Results: The TCP increased from a median (range) of 0.45 
(0.08-0.83) with the conventional approach to 1.0 (no range) 
with the focal boost. While there were only minor differences 
in the rectum NTCPs with vs. without the boost there were 
considerable differences in the NTCP for the bladder for two 
of the patients (more than a doubling of the NTCP with the 
boost; Table 1). These two patients had the index lesion that 
was closest to the bladder. 
 
 
 
 
 
Conclusion: We have established a biological modelling 
based method to identify prostate cancer patients where the 
focal boost cannot be achieved with state of the art photon-
based treatment without a considerable increase in the 
NTCPs. Further work will consider the feasibility of proton 
planning, given both inter- and intra-fractional organ motion 
patterns.  
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Purpose or Objective: This study presents a universally 
applicable decision support system (DSS), with respect to the 
prediction of five-year biological no evidence of disease (5y-
bNED) for localised prostate cancer (PCa) patients treated by 
external beam radiation therapy (EBRT). 
 
Material and Methods: To develop a DSS this study utilised 
the traditional approach of model training based upon meta-
analysis data (MAD: n=5218) from the literature with model 
validation based upon routine clinical care data (CCD: n=827) 
from clinics with a rapid learning healthcare (RLHC) 
environment. The following standard clinical features for PCa 
patients were investigated to train and validate a tumour 
control probability model (TCP) and a predictive machine 
learning model (PML): primary tumour stage (T), lymph node 
stage (N), metastasis stage (M), prostate specific antigen 
(PSA), Gleason score (GS), clinical-target-volume (CTV), total 
dose (D), and fractional dose (d). These features were 
selected as they are typically known within all clinics treating 
PCa patients, thus maximising the generalizability of the DSS. 
 
Results: The DSS is comprised of two distinct models. The 
TCP model was found to be well calibrated with poor 
discriminative ability. Training resulted in an adjusted 
weighted R2 value of 0.76, a weighted mean absolute 
residual (wMAR) of 4.7% and an area under the curve (AUC) of 
0.67 [0.65, 0.69]. Validation resulted in an adjusted weighted 
R2 value of 0.51, a wMAR of 2.0% and an AUC of 0.57 [0.51, 
0.63]. Contrastingly, the PML model was found to be poorly 
calibrated with good discriminative ability. Training resulted 
in an adjusted weighted R2 value of 0.27, a wMAR of 8.3% 
and an AUC of 0.66 [0.64, 0.68]. Validation resulted in an 
adjusted weighted R2 value of 0.90, a wMAR of 16.2% and an 
AUC of 0.61 [0.56, 0.65]. Subset analysis shows that the DSS 
performs best in high-risk PCa patients with validation 
resulting in an AUC of 0.66 [60, 0.72] with a wMAR of 1.0%. 
 
Conclusion: A DSS developed with MAD has been validated in 
CCD extracted using RLHC infrastructure. The DSS uses 
standard clinical features to estimate with good accuracy 
(wMAR < 4.7%) and reasonable fidelity (AUC > 0.61) the 5y-
bNED rate and classification, respectively, of PCa patients. 
The performance of the DSS in the validation high-risk PCa 
cohort (wMAR = 1%) and patients (AUC = 0.66) for whom 
therapy could be potentially adapted or individualised based 
on the DSS has clinical relevance and should be prospectively 
validated. 
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Purpose or Objective: The use of biological information on 
tumour control and normal-tissue complications for 
treatment plan optimisation can be used for individualising 
the dose prescription. For patients with prostate cancer, 
moreover, the tumour localisation by means of MR-images 
facilitates the use of such information for a simultaneous 
dose escalation in the so-called dominant intraprostatic 
lesions (DIL), thus further improving the treatment outcomes. 
However, a correct modelling of the tumour-control 
